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The aim of this study was to compare the effect of antimuscarinic antagonists on carbachol-induced
contraction of normal human bladder and detrusor overactivity associated with benign prostatic hy-
perplasia (DO/BPH). Samples of human bladder muscle were obtained from patients undergoing total
cystectomy for bladder cancer (normal bladder), and those undergoing retropubic prostatectomy for
BPH. All of the patients with DO/BPH had detrusor overactivity according to urodynamic studies.
Detrusor muscle strips were mounted in 10-ml organ baths containing Krebs solution, and concentration
eresponse curves for carbachol were obtained in the presence of antimuscarinic antagonists (4-DAMP,
methoctramine, pirenzepine, tolterodine, solifenacin, trospium, propiverine, oxybutynin, and imidafe-
nacin) or vehicle. All antagonists competitively antagonized concentrationeresponse curves to carbachol
with high afﬁnities in normal bladder. The rank order of mean pA2 values was as follows: trospium
(10.1) > 4-DAMP (9.87), imidafenacin (9.3) > solifenacin (8.8) > tolterodine (8.6) > oxybutynin
(8.3) > propiverine (7.7) > pirenzepine (7.4) > methoctramine (6.6). The effects of these antimuscarinic
antagonists did not change when tested with DO/BPH bladder, suggesting that each antimuscarinic
antagonist has a similar effect in this condition. Schild plots showed a slope corresponding to unity,
except for propiverine with DO/BPH detrusor. In conclusion, M3-receptors mainly mediate contractions
in human bladder strips with normal state and DO/BPH.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
For pharmacological treatment of overactive bladder (OAB),
antimuscarinic agents have long been the drugs of choice. However,
these agents can have unpleasant side effects, such as dry mouth,
constipation, headache, blurred vision, and tachycardia, while the
lower urinary tract symptoms of some patients are refractory
(1e4). Worldwide, six antimuscarinic drugs are currently marketed
for the treatment of OAB, which are oxybutynin, tolterodine, pro-
piverine, trospium, darifenacin, and solifenacin (2,5). Recently,Continence Center, Dokkyo
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manishi).
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d/4.0/).imidafenacin and fesoterodine were also developed, and were re-
ported to be effective for OAB (4,6e8).
The smooth muscle of the urinary bladder, like the majority of
smooth muscle in many species, expresses a heterogeneous pop-
ulation of muscarinic receptors. Predominance of the M2 musca-
rinic receptor subtype, with a minor population of M3 receptors,
has been reported in the bladder smooth muscle of several species.
The proportion of muscarinic M2 and M3 receptors has been re-
ported to be 70e80% and 20e30%, respectively, in the bladder
smooth muscle of humans, guinea pigs, and rabbits (9e11). How-
ever, pharmacological characterization of the muscarinic receptor
mediating detrusor muscle contraction in pigs and humans has
suggested that only the M3 receptor is involved (9,11,12). This
suggests that the M3 receptor is the predominant muscarinic re-
ceptor subtype responsible for detrusor muscle contraction in
response to muscarinic agonists, while the M2 receptor is not
directly involved (11,13).nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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the contractile response of both rat and human bladder smooth
muscle under pathologic conditions. M2 receptors have been re-
ported to mediate detrusor contraction in rats with pelvic nerve
denervation or spinal cord transection, and in patients with
neurogenic bladder dysfunction (14e16). An increase of total
muscarinic receptor density and M2 receptor density along with a
reduction of M3 receptor density have been reported in obstructed,
hypertrophic rat bladders (17). In contrast, the bladder contractile
response to carbachol was reported to be mediated by the M3 re-
ceptor in rats with partial bladder outlet obstruction and in humans
with idiopathic or neurogenic OAB (18,19). The present study was
performed to investigate whether the antagonist effect of various
antimuscarinic agents on carbachol-induced contraction differed
between normal human bladder muscle and detrusor overactivity
(DO) in patients with benign prostatic hyperplasia (BPH).
2. Materials and methods
The procedures were approved by the local ethics committee of
Dokkyo Medical University, and written informed consent was
obtained from each patient before enrollment. Tissue samples
(8 2mm) were obtained from the dome of the bladder in patients
without lower urinary tract symptoms undergoing total cystectomy
for bladder cancer (normal bladder), and in patients undergoing
retropubic prostatectomy for BPH whose bladders showed DO (DO/
BPH). The serosa and urothelium were removed. A section of
bladder dome tissue was dissected from an area free of cancer for
use in the study. All of the patients with DO/BPH were proven to
have DO and bladder outlet obstruction by video-urodynamic
studies or ambulatory urodynamic studies before surgery. Muscle
strips were mounted in 10 ml organ baths containing Krebs solu-
tion (in mM: NaCl 118.4, KCl 4.7, CaCl2 1.9, NaHCO3 24.9, MgSO41.15,
KH2PO4 1.15, and glucose 11.7), which was maintained at 37 C and
aerated continuously with 95% O2 and 5% CO2. The strips were
placed under a resting tension of 1 g (9.8 mN) and allowed to
equilibrate for 60 min, during which time they were washed every
10 min and the resting tensionwas adjusted. The isometric tension
generated by each muscle specimen was measured by a Power Lab
data acquisition system (Analog Digital Instruments, Sydney, New
South Wales, Australia).
Cumulative concentrationeresponse curves (CRCs) for carba-
chol were obtained. Then each muscle strip was washed for about
45 min until a stable resting tension was attained, followed by
equilibration for 30 min with Krebs solution containing the
appropriate concentration of antagonist or vehicle (time control).
After incubation for 30 min, a second CRC for carbachol was ob-
tained in the continued presence of the antagonist or vehicle. An-
tagonists were added at increasing concentrations after washing
for 45 min. In this way, 4 CRCs for carbachol were obtained from
each muscle strip, with three being obtained in the presence of
increasing concentrations of a muscarinic antagonist {(4-DAMP (3,
10, 30 nM), methoctramine (1, 3 and 10 mM), pirenzepine (1, 3 and
10 mM), tolterodine (3, 10, 30 nM), solifenacin (3, 10, 30 nM),
trospium (3, 10, 30 nM), propiverine (10, 30, 100 nM), oxybutynin
(3,10,30 nM), or imidafenacin (3,10,30 nM)} or in the presence of
the vehicle. Control experiments were performed with addition of
the vehicle instead of an antagonist and the data were used to
correct for any tachyphylaxis or time-dependent changes of tissue
sensitivity and responsiveness. The correction factors for EC50 and
the maximum response between the ﬁrst and second curves were
both 1.0, those between the ﬁrst and third curves were 1.5, and
0.85, respectively, and those between the ﬁrst and fourth curves
were 2.8 and 0.67, respectively. These correction factors were
applied in all experiments (9,11e13,18).2.1. Statistical analysis
The agonist potency and maximum response were expressed as
the mean pEC50 ± SEM (logarithm of the molar concentration of
agonist resulting in 50% of the maximum response) and the mean
maximum contraction ± SEM, respectively. The pA2 value for a
muscarinic receptor antagonist (determined as the x-intercept on
the Schild regression plot) was only measured when the Schild plot
slope was unity. The dissociation constant (apparent KB value) for
each antagonist was calculated from the following equation:
KB ¼ antagonist concentration (molar) (concentration ratio  1)1
where the concentration ratio is the ratio of EC50 values obtained in
the presence and absence of the antagonist. Data are normalized for
themaximal response in the ﬁrst (control) curve, and are expressed
as the mean ± SEM. The unpaired Student's t-test was used for
statistical comparison of normal bladder and DO/BPH bladder
tissues.
2.2. Drugs and chemicals
Carbachol (carbamylcholine chloride), 4-diphenyl acetoxy-
methyl piperidine methiodide (4-DAMP), methoctramine, pir-
enzepine, oxybutynin, and propiverine were purchased from Sigma
Chemical (St Louis, MO., USA). Tolterodine, trospium, solifenacin
and imidafenacin were kind gifts from Pﬁzer Inc (New York, USA),
Nihon Kemifa Ltd. (Tokyo, Japan), Asteras Ltd. (Tokyo, Japan), and
Kyorin Ltd. (Tokyo, Japan), respectively.
3. Results
Carbachol induced concentration-dependent contraction of
normal bladder strips, with a mean pEC50 value and maximum
response of 6.5 ± 0.1 and 9.6 ± 0.7 g, respectively. Carbachol also
induced concentration-dependent contraction of DO/BPH bladder
strips, with a mean pEC50 value andmaximum response of 6.4 ± 0.1
and 9.8 ± 1.0 g, respectively. Both the mean pEC50 value and the
maximum response did not differ signiﬁcantly between the two
tissues.
4-DAMP (a selective M3-muscarinic receptor antagonist) and
methoctramine (a selective M2-muscarinic receptor antagonist)
produced parallel, rightward displacement of the CRCs to carbachol
without affecting maximum responses and yielded mean (±SEM)
pA2 values of 9.87±0.09 and 6.64±0.05, respectively in bladder
strips from normal bladder. The pA2 values for 4-DAMP and
methoctramine decreased signiﬁcantly (P ¼ 0.0004 and P ¼ 0.0347,
respectively) in bladder strips from DO/BPH compared with the
normal bladder (Table 1). Schild slopes for 4-DAMP and
methoctramine did not change signiﬁcantly (Figs. 1 and 2).
Pirenzepine (a selective M1-muscarinic receptor antagonist)
also produced parallel, rightward displacement of the CRCs to
carbachol without affecting maximum responses and yieldedmean
(±SEM) pA2 values of 7.38±0.09 and Schild slopes not signiﬁcantly
different from unity. The pA2 values and Schild slopes for pir-
enzepine did not change signiﬁcantly in bladder strips from DO/
BPH (Table 1).
Tolterodine, trospium and propiverine (nonselective anti-
muscarinic antagonists), and oxybutynin, solifenacin and imidafe-
nacin (M1- and M3-selective antimuscarinic antagonists) also
caused parallel, rightward displacement of the CRCs for carbachol
without affecting the maximum response for strips of normal and
DO/BPH bladder, respectively. The mean (±SEM) pA2 value and
Schild plot slope for the effect of each muscarinic antagonist on the
CRCs for carbachol are summarized in Table 1. The pA2 values of
these muscarinic antagonists did not differ signiﬁcantly between
the normal bladder and DO/BPH bladder. In addition, the slope of
Table 1
Antagonist afﬁnities and Schild slopes of muscarinic antagonists against concentrationeresponse curves to carbachol in the muscle strips of normal human detrusor and
overactive detrusor associated with benign prostatic hyperplasia (DO/BPH).
Antagonist 4-DAMP Methoctramine Pirenzepine
Normal bladder N ¼ 9 N ¼ 6 N ¼ 4
pA2 ± SEM 9.87±0.09 6.64 ± 0.05 7.38 ± 0.09
Schild slope 1.09 ± 0.37 0.69 ± 0.01 0.77 ± 0.17
DO/BPHb N ¼ 5 N ¼ 5 N ¼ 5
pA2 ± SEM 9.01 ± 0.12c 6.36 ± 0.09c 7.33 ± 0.11
Schild slope 0.93 ± 0.15 0.76 ± 0.18 0.89 ± 0.42
Antagonist Tolterodine Trospium Propiverine Oxybutynin Solifenacin Imidafenacin
Normal bladder N ¼ 6 N ¼ 5 N ¼ 6 N ¼ 4 N ¼ 8 N ¼ 6
pA2 ± SEM 8.63 ± 0.17 10.12 ± 0.11 7.74 ± 0.20 8.33 ± 0.16 8.80 ± 0.10 9.29 ± 0.26
Schild slope 1.29 ± 0.01 0.91 ± 0.29 1.06 ± 0.20 1.01 ± 0.12 1.06 ± 0.20 0.93 ± 0.12
DO/BPHb N ¼ 5 N ¼ 7 N ¼ 5 N ¼ 4 N ¼ 5 N ¼ 6
pA2 ± SEM 8.74 ± 0.16 10.14 ± 0.64 7.60 ± 0.11 8.41 ± 0.12 8.73 ± 0.09 9.24 ± 0.09
Schild slope 1.23 ± 0.06 1.04 ± 0.44 0.49 ± 0.14a 1.16 ± 0.11 0.98 ± 0.04 1.22 ± 0.17
a The Schild slope was different from unity in tissues from DO/BPH patients, and decreased signiﬁcantly compared to that of normal bladder (P ¼ 0.0476). Apparent pKB
values were calculated because of non-competitive antagonism.
b Detrusor overactivity associated with benign prostatic hyperplasia.
c The pA2 values for 4-DAMP andmethoctramine decreased signiﬁcantly (P¼ 0.0004 and P¼ 0.0347, respectively) in bladder strips from DO/BPH compared with those from
the normal bladder.
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change signiﬁcantly, except for propiverine with DO/BPH muscle
strips. The Schild slope for propiverine were different from unity in
tissues from DO/BPH patients, and decreased signiﬁcantly
compared to that of normal bladder (P ¼ 0.0476).
The rank order of pA2 value of muscarinic antagonists in the
normal bladder was, trospium (10.1) > 4-DAMP (9.9) > imidafena-
cin (9.3) > solifenacin (8.8) > tolterodine (8.6) > oxybutynin
(8.3) > propiverine (7.7) > pirenzepine (7.4) >methoctramine (6.6).
That in DO/BPH was, trospium (10.1) > imidafenacin (9.2) > 4-
DAMP (9.0) > solifenacin (8.7) ¼ tolterodine (8.7) > oxybutynin
(8.4) > propiverine (7.6) > pirenzepine (7.3) >methoctramine (6.4).
4. Discussion
Detrusor overactivity (DO) has been reported to be the cause of
overactive bladder symptoms. It has been reported that DO is noted
in 40e60% of patients with BPH (20). Bladder outlet obstruction in
BPH can be a factor contributing to DO, possibly through cholin-
ergic denervation of the detrusor and hypersensitivity of musca-
rinic receptors to acetylcholine, although the prevalence of OAB is
similar in men and women across the age groups (2). Anti-
muscarinic agents are the most widely used treatment for OAB,
including urgency incontinence (1). Each of the antimuscarinic
drugs has demonstrated efﬁcacy against OAB symptoms, but their
pharmacokinetics and adverse event proﬁles differ somewhat due
to differences of structure (tertiary vs. quaternary amines),
muscarinic receptor subtype selectivity, and organ selectivity (1,2).
Among the various antimuscarinic agents, trospium, propiverine
and tolterodine have a non-selective antimuscarinic action, while
oxybutynin, solifenacin, and imidafenacin show selectivity for the
M3 and M1 muscarinic receptor subtypes.
The muscarinic antagonists tested in the present study
demonstrated competitive antagonism with Schild slopes not
different from unity in the normal bladder. Afﬁnity values were the
highest for 4-DAMP (a selective M3-muscarinic receptor antago-
nist), followed by pirenzepine (a selective M1-muscarinic receptor
antagonist) and methoctramine (a selective M2-muscarinic recep-
tor antagonist). These afﬁnity values were comparable with the
previous results in pig and human, indicating that M3-muscarinic
receptor predominantly mediates contraction in human detrusor in
normal state (11,13,18).The afﬁnity values of 4-DAMP and methoctramine decreased
signiﬁcantly in pathologic states in DO/BPH. However the afﬁnity
value of pirenzepine and the rank order of these muscarinic an-
tagonists did not change in this pathologic condition indicating that
M3-receptor still predominantly mediated contraction in this
pathological condition. The antagonist activity may not be the same
between in the normal and in the pathologic state. We cannot
explain the reasons, but one of the reasons may be that the uro-
theliumwas removed in the present study because the presence of
urothelium may inﬂuence contraction of the detrusor. The purpose
of this study was to investigate whether the antagonist afﬁnity of
bladder smooth muscle changed between the normal and the
pathological states. Thus we have removed the urothelium to study
solely the afﬁnity of muscarinic receptor subtypes for the bladder
smooth muscle. The afﬁnity of these muscarinic antagonists may
have changed when the urothelium was intact. The further study
remains to be necessary to investigate the interaction of urothelium
and detrusor.
Tolterodine is a nonselective antimuscarinic agent that is widely
used for the treatment of OAB, and it has been reported to be safe
and effective for overactive bladder in men with BPH (21,22). The
afﬁnity (pA2) value of tolterodine against CRC to carbachol in our
study in the human bladder from normal and DO/BPH appeared to
be similar to the previous reports in the normal human bladder
(23).
Solifenacin and imidafenacin are antimuscarinic drugs that are
widely used for the treatment of OABwith selectivity for M3 andM1
muscarinic receptor subtypes (3,4,24), and the afﬁnity values for
normal human bladder in the previous report were also similar to
our result for bladder muscle strips from normal states and DO/BPH
(7,25).
Propiverine has a nonselective antimuscarinic action and is also
a calcium antagonist; it has been widely used in Japan and Europe
(26), and the afﬁnity values for normal human bladder in the
previous report were also similar to our result for bladder muscle
strips fromnormal states and DO/BPH (7,25). However, the slope for
Schild plot was less than unity in propiverine with DO/BPO muscle
strips (0.49 ± 0.14). The reason may be that propiverine also shows
activity as a calcium antagonist, so both its antimuscarinic and
calcium antagonist effects may have operated in DO/BPO.
The present study showed that all of the muscarinic antagonists
tested, including clinical available antimuscarinic agents
Fig. 1. Effects of 4-DAMP on concentrationeresponse curves to carbachol and Schild plot in normal bladder (upper panel) and detrusor overactivity due to benign prostatic hy-
perplasia (DO/BPH; lower panel).
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imidafenacin) competitively antagonized carbachol responses with
high afﬁnity in normal human detrusor. The rank order of their pA2
value was as follows: trospium (10.1) > 4-DAMP (9.9) > imidafena-
cin (9.3) > solifenacin (8.8) > tolterodine (8.6) > oxybutynin
(8.3) > propiverine (7.7) > pirenzepine (7.4) >methoctramine (6.6).
The pA2 values did not differ signiﬁcantly between the normal state
and detrusor overactivity (DO/BPH). The pA2 values for these
antimuscarinic agents and their rank order seemed to be similar to
those in previous reports. Chess-Williams et al. (9), and Sellers et al.
(12), reported that the antagonistic afﬁnity of various muscarinic
antagonists was best correlated with the afﬁnity for cloned M3
muscarinic receptor subtype. These observations suggest that the
M3 receptor is the predominant muscarinic receptor subtype
mediating detrusor contraction in response to muscarinic agonists,
while the M2 receptor is not directly involved in contraction of the
normal bladder (1,2,9,12). Reports about the role of the M2 receptor
in animal models of detrusor overactivity have been conﬂicting.
Braverman and Ruggieri (17) found a signiﬁcant increase of M2
receptor mRNA transcript and protein levels in hypertrophic uri-
nary bladders after major pelvic ganglion electrocautery and partial
bladder outlet obstruction. However, the M3 receptor protein level
was reported to be decreased (although M3-receptor transcriptionwas increased) in hypertrophic bladders after bladder outlet
obstruction. There was a shift in the afﬁnity of muscarinic antag-
onists towards M2-mediated contraction in addition to muscarinic
supersensitivity in rat models of neurogenic bladder (denervation
and spinal cord injury) (14,15). On the contrary, Krichevsky et al.
(19), found no change in the afﬁnity of muscarinic antagonists
between the normal bladder and partial bladder outlet obstruction
in rats. In humans, Pontari et al. (16), reported that the M2 receptor
played a role in the contraction of overactive detrusor muscle in
patients with neurogenic bladder. However, Stevens et al. (18), re-
ported no change in the afﬁnity of muscarinic antagonists between
normal and overactive (idiopathic and neurogenic) detrusor muscle
in humans.
Limitation of this study is that it is difﬁcult to get human
detrusor tissues, similar to other studies (7,9e13). As a control, we
collected bladder tissues from patients undergoing total cys-
tectomy for bladder cancer. We selected patients without lower
urinary tract symptoms, but we could not exclude patients with DO
because we could not perform urodynamic study in these patients
for ethical reasons. It was more difﬁcult and limited to obtain hu-
man bladder tissues from patients undergoing retropubic prosta-
tectomy because transurethral resection of prostate is the mainstay
of surgery for BPH.
Fig. 2. Effects of methoctramine on concentrationeresponse curves to carbachol and Schild plot in normal bladder (upper panel) and detrusor overactivity due to benign prostatic
hyperplasia (DO/BPH; lower panel).
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dependent contraction with a similar potency (pEC50) and
maximal effect in strips of both normal and DO/BPO detrusor
muscle. This result was different from that reported by Stevens et al.
(18), who found an increase of sensitivity to muscarinic agonists
(pEC50), highlighting a change of receptor-mediated contraction in
idiopathic and neurogenic DO compared with the normal detrusor.
The reasons for the discrepancy are unknown, but may be related to
differences of the underlying disease (idiopathic or neurogenic OAB
vs. BPH).
The above results suggest that antimuscarinic agents are effec-
tive for DO/BPO, and that theM3 receptor mainly mediates detrusor
contraction in this condition.
Although the role of M2 receptor could not be demonstrated in
this present study, it may have effects when M3 receptor was
inactivated (11,13). M2 receptor in the urothelium may also have a
role in activating afferent c-ﬁbers in the pathological conditions
(27). The role of M2 receptor should be elucidated in the future
studies.5. Conclusions
4-DAMP, a selective M3-receptor antagonist, oxybutynin, sol-
ifenacin and imidafenacin, selective M1- and M3-receptorantagonists, and trospium, tolterodine and propiverine, non-
selective muscarinic receptor antagonists antagonized CRCs to
carbachol with high afﬁnities. Methoctramine, a selective M2-re-
ceptor antagonist, and pirenzepine, a selective M1-receptor antag-
onist antagonized carbachol-induced contractions with relatively
low afﬁnities. These results suggest that M3-receptors mainly
mediate contractions in normal human bladder. The rank order of
the afﬁnity values of these antimuscarinic antagonists did not
change when tested with DO/BPH bladder, suggesting that each
antimuscarinic antagonist has a similar effect in this condition.
Schild plots showed a slope corresponding to unity, except for
propiverine with DO/BPH detrusor. In conclusion, M3-receptors
mainly mediate contractions in human bladder strips with normal
state and DO/BPH.Conﬂicts of interest
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